Core Insights - Rhythm Pharmaceuticals announced topline results from its EMANATE trial, indicating that four substudies did not meet their primary endpoints [1][2] - Despite the disappointing primary results, the company noted encouraging signals from additional analyses of specific substudies, which may inform future development of next-generation MC4R agonists [2][4] Study Overview - EMANATE was a global, randomized, double-blind, placebo-controlled Phase 3 trial designed to evaluate the efficacy and safety of setmelanotide in patients with rare, genetically-driven obesities of the MC4R pathway [2][3] - The trial included four independent genetic substudies focusing on patients with obesity due to heterozygous variants of the POMC/PCSK1, LEPR, SRC1, and SH2B1 genes [2] Topline Results - The primary endpoint was the difference in mean percent change in BMI from baseline to Week 52 versus placebo [3] - Post hoc analyses showed statistically significant and clinically meaningful BMI reductions at Week 52 in the POMC/PCSK1 Hets and SRC1 substudies [3][4] - Specific results included a 5.5% least-squares mean difference in BMI for POMC/PCSK1 Hets patients and a 6.2% difference for SRC1 patients, both statistically significant [5] Safety Profile - No new safety signals were observed with setmelanotide, and the safety profile was consistent with prior studies [3] - Common treatment-emergent adverse events included skin hyperpigmentation, injection site reactions, nausea, vomiting, and headache [3][20] Future Plans - The company plans to continue analyzing the EMANATE dataset and evaluate potential clinical development paths for SRC1 and POMC with next-generation MC4R agonists [4][6] - Rhythm is also advancing a broad clinical development program for setmelanotide and investigational MC4R agonists [9]

Financial Data and Key Metrics Changes - Revenue from sales of IMCIVREE was $57.3 million for Q4 2025, representing a quarter-over-quarter increase of 12% and $194.8 million for the full year, an increase of approximately 50% from 2024 [30][31] - Gross to net for US sales was approximately 84.6%, generally in line with previous quarters [33] - GAAP EPS for Q4 2025 was a net loss per basic and diluted share of $0.73, including $0.02 per share from accrued dividends on convertible preferred stock [36] Business Line Data and Key Metrics Changes - In Q4 2025, $39 million, or 68% of product revenue, was generated in the United States, and $18.3 million, or 32% of product revenue, was generated outside the United States [31] - The volume of vials shipped to specialty pharmacy in the US was approximately 1.7 million greater than the vials dispensed to patients, resulting in a negative $1.3 million inventory swing from Q3 to Q4 [32] - Research and development expenses were $42 million for Q4, compared to $41.2 million in the same quarter last year [34] Market Data and Key Metrics Changes - The company identified approximately 40 priority medical centers in the US based on significant concentrations of Acquired Hypothalamic Obesity (AHO) patients [21] - The estimated prevalence of Acquired HO in the US is around 10,000 patients, representing a significant opportunity for the company [19] Company Strategy and Development Direction - The company is preparing for the launch of Acquired Hypothalamic Obesity pending regulatory approval, with a PDUFA goal date of March 20 [19] - The company plans to run the Phase 3 trial for bivamelagon largely in countries where setmelanotide will not be available for acquired HO in the near future [14] - The company anticipates launching in Japan within the next 12 months, with a strong leadership team already in place [80] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth of the BBS opportunity, highlighting the steady rate of growth in both US and ex-US markets [6] - The management team noted that the FDA meeting regarding bivamelagon was highly constructive, confirming readiness to move to Phase 3 [13] - Management acknowledged the challenges in the PWS study but remains optimistic about the potential for positive outcomes [51] Other Important Information - The company ended 2025 with approximately $389 million in cash equivalents and short-term investments, expected to fund planned operations for at least 24 months [36] - The company anticipates non-GAAP operating expenses for 2026 to be approximately $385 million-$415 million, reflecting a year-over-year increase driven by clinical program success [39] Q&A Session Summary Question: Update on bivamelagon phase 3 trial - Management confirmed that the trial will largely mimic the phase 3 of setmelanotide, with no specific changes to enrollment criteria [43] Question: Guidelines for HO treatment - Management indicated that while current guidelines suggest a 6-month wait post-surgery, feedback suggests earlier intervention may be beneficial [46] Question: Update on PWS study - Management stated that they are on track for a mid-year update and are looking for a minimum of 5% BMI change as a goal [51] Question: Trends in IMCIVREE sales - Management noted potential dampening of sales in Q1 due to inventory dynamics but did not provide specific growth estimates [55] Question: Dosing in bivamelagon phase 3 trial - Management confirmed that dosing will escalate from 200 mg to 600 mg, with 600 mg as the target dose [74] Question: Opportunity in Japan - Management estimated the prevalence of AHO in Japan to be between 5,000 and 8,000 patients, with plans for a launch within 12 months [80]

Financial Data and Key Metrics Changes - The company reported global revenue of $48.5 million for Q2 2025, representing a 29% increase quarter over quarter [38] - U.S. revenue accounted for 66% of total revenue, amounting to $32 million, while international revenue was $16.5 million, making up 34% [38] - Year-over-year, net product revenues increased by $19.4 million or 67% compared to Q2 2024 [41] - The company ended Q2 2025 with $291 million in cash, following an oversubscribed equity offering that raised $189.2 million [35][37] Business Line Data and Key Metrics Changes - The company experienced solid growth in VVS sales, with a focus on BBS and acquired hypothalamic obesity [8][10] - The cumulative number of BBS prescribers grew by 38% from Q2 2024 to Q2 2025, with a 9% increase in cumulative prescribers from Q1 2025 [22] - The number of reimbursed patients on therapy in the U.S. grew at mid-single-digit percentage rates [38] Market Data and Key Metrics Changes - The international market saw a steady increase in patients on therapy, particularly in France and Italy, driven by early access programs for hypothalamic obesity [29][40] - The company is expanding its presence in new countries, including Poland and the Czech Republic, with ongoing efforts in Japan [30] Company Strategy and Development Direction - The company aims to leverage its learnings from the BBS launch to prepare for the launch of Encepria in hypothalamic obesity, pending FDA approval [25][27] - The company is focused on long-term growth, with confidence in the sustainability of its revenue streams from rare diseases [9][100] - The company plans to continue expanding its market presence globally, with a focus on both existing and new markets [98][100] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the importance of the recent quarter in laying the foundation for significant growth [7][10] - The company is confident in the projected epidemiology for acquired hypothalamic obesity, estimating a patient population of 5,000 to 10,000 in the U.S. [11][26] - Management noted that the company is well-capitalized and has a cash runway of at least 24 months, indicating strong financial health [37] Other Important Information - The company is on track for U.S. and European regulatory filings in Q3 for semolantide in hypothalamic obesity [18] - The company has a robust pipeline with multiple upcoming milestones, including data releases and trial enrollments planned for 2026 [18][19] Q&A Session Summary Question: Upcoming pipeline catalyst regarding Prader Willi data - Management characterized the Prader Willi study as exploratory, with a focus on higher dosing and longer duration compared to previous trials [49][50] Question: Expected follow-up for Prader Willi study - Management indicated that patients will continue treatment beyond the initial six months if they show benefits, emphasizing the importance of long-term data [58] Question: Confidence in higher prevalence estimates for hypothalamic obesity - Management noted ongoing fieldwork and claims data analysis to support confidence in the higher end of the prevalence range [75] Question: Growth expectations for international markets - Management highlighted that while recent growth has been strong, Q3 may see a quieter period due to seasonal factors [78] Question: Off-label usage in the U.S. for hypothalamic obesity - Management confirmed minimal off-label usage currently, with a focus on adhering to approved indications [86]